title: Postoperative statin therapy attenuates the intensity of systemic inflammation and increases fibrinolysis after coronary artery bypass grafting.
abstract: A total of 25 patients undergoing coronary artery bypass grafting (CABG) were included in the study. Patients received statin (20 mg daily) postoperatively for 2 weeks. All analyses were performed at 2 different time points: preoperatively (group 1) and 2 weeks after operation (group 2). Interleukin (IL)-6, IL-8, plasminogen activator inhibitor 1 (PAI-1), tumor necrosis factor α (TNF-α), tissue plasminogen activator (t-PA) levels, and tissue factor pathway inhibitor (TFPI) were evaluated. Statin treatment caused a significant reduction in the plasma level of PAI-1 (preop: 15.04 ± 0.13 ng/mL vs postop: 13.89 ± 2.14 ng/mL; P < .05) and increased t-PA levels (preop: 109.74 ± 0.13 vs postop: 231.40 ± 1.22 ng/mL; P < .001). Plasma TNF-α and IL-6 levels did not change with treatment. Statin treatment caused a significant reduction in plasma IL-8 level (279.70 ± 3.42 ng/mL vs postop: 207.18 ± 3.63 ng/mL, P < .05), and TFPI (4.87 ± 2.05 ng/mL vs postop: 6.27 ± 1.25 ng/mL; P < .05). The results demonstrate that atorvastatin attenuates systemic inflammatory reaction after cardiac surgery.
authors.affiliation: Department of Biochemistry, Faculty of Pharmacy, Marmara University, Istanbul, Turkey. stetik@marmara.edu.tr
authors.forename: Sermin
authors.initials: S
authors.lastname: Tetik
authors.forename: Koray
authors.initials: K
authors.lastname: Ak
authors.forename: Yucel
authors.initials: Y
authors.lastname: Sahin
authors.forename: Ozkan
authors.initials: O
authors.lastname: Gulsoy
authors.forename: Selim
authors.initials: S
authors.lastname: Isbir
authors.forename: Sinan
authors.initials: S
authors.lastname: Arsan
authors.forename: Turay
authors.initials: T
authors.lastname: Yardimci
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D001026:Coronary Artery Bypass; D016207:Cytokines / Q000097:blood; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy*; D011758:Pyrroles / Q000008:administration & dosage*; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D016207:Cytokines; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; D011758:Pyrroles; C051321:SERPINE1 protein, human; C051928:lipoprotein-associated coagulation inhibitor; D000069059:Atorvastatin; D010959:Tissue Plasminogen Activator